share_log

12 Health Care Stocks Moving In Wednesday's After-Market Session

Benzinga Real-time News ·  Jan 11, 2023 16:32

Gainers

  • Yield10 Bioscience (NASDAQ:YTEN) shares increased by 59.5% to $3.35 during Wednesday's after-market session. This security traded at a volume of 341.5K shares come close, making up 1423.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.5 million.
  • electroCore (NASDAQ:ECOR) shares increased by 7.56% to $0.3. The company's market cap stands at $21.1 million.
  • SAB Biotherapeutics (NASDAQ:SABS) stock increased by 5.94% to $0.77. The company's market cap stands at $38.9 million.
  • Revance Therapeutics (NASDAQ:RVNC) shares increased by 5.3% to $28.18. The market value of their outstanding shares is at $2.3 billion.
  • Aveanna Healthcare Hldgs (NASDAQ:AVAH) stock moved upwards by 5.0% to $1.05. The market value of their outstanding shares is at $195.2 million.
  • ProPhase Labs (NASDAQ:PRPH) stock rose 4.94% to $9.76. The company's market cap stands at $158.8 million.

Losers

  • NeuroOne Medical Tech (NASDAQ:NMTC) shares declined by 8.7% to $1.26 during Wednesday's after-market session. The market value of their outstanding shares is at $20.4 million.
  • Fresh Tracks Therapeutics (NASDAQ:FRTX) shares fell 7.07% to $1.71. Today's trading volume for this security ended up closing at 716.8K shares, which is 1732.9 percent of its average volume over the last 100 days. The company's market cap stands at $5.1 million.
  • Comera Life Sciences (NASDAQ:CMRA) stock declined by 5.93% to $1.43. The company's market cap stands at $31.8 million.
  • Minerva Neurosciences (NASDAQ:NERV) shares fell 5.71% to $2.15. The company's market cap stands at $11.4 million.
  • X4 Pharmaceuticals (NASDAQ:XFOR) stock fell 5.36% to $1.06. The market value of their outstanding shares is at $128.2 million.
  • Venus Concept (NASDAQ:VERO) shares declined by 5.03% to $0.3. The company's market cap stands at $20.4 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment